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ABSTRACT
Cabergoline is a new, long acting, dopamine agonist that is more
effective and better tolerated than bromocriptine in patients with
hyperprolactinemia. Because dopamine agonists still have a place in
the medical management of acromegaly, cabergoline might be a useful
treatment.
We, therefore, evaluated the effect of long term administration of
cabergoline in a large group of unselected acromegalic patients. Sixty-
four patients were included in a multicenter, prospective, open la-
beled study. A subgroup of 16 patients had GH-/PRL-cosecreting
pituitary adenomas. Cabergoline was started at a dose of 1.0 mg/week
and was gradually increased until normalization of plasma insulin-
like growth factor I (IGF-I) levels, occurrence of unacceptable side-
effects, or a maximal weekly dose of 3.5 mg (7.0 mg in 1 case) was
reached.
Treatment with cabergoline suppressed plasma IGF-I below 300
mg/L in 39% of cases and between 300–450 mg/L in another 28%. With
pretreatment plasma IGF-I concentrations less than 750 mg/L, a sup-
pression of IGF-I below 300 mg/L was obtained in 53% of cases, and
a suppression between 300–450 mg/L was obtained in another 32%.
By contrast, with pretreatment plasma IGF-I concentrations above
750 mg/L, only 17% of cases showed a suppression of IGF-I below 300
mg/L, and there was IGF-I suppression between 300–450 mg/L in
another 21%. In GH-/PRL-cosecreting adenomas, 50% of cases sup-
pressed plasma IGF-I levels below 300 mg/L, and another 31% did so
between 300–450 mg/L, in contrast to only 35% and 27%, respectively,
in GH-secreting adenomas.
Similar results were obtained concerning the secretion of GH.
Tumor shrinkage was demonstrated in 13 of 21 patients, with a mass
reduction by more than half in 5 GH-/PRL-cosecreting adenomas.
Except for slight gastrointestinal discomfort and orthostatic hypo-
tension in a few patients at the beginning of therapy, cabergoline
treatment was well tolerated. Only 2 patients stopped medication
because of nausea. The weekly dose of cabergoline ranged between
1.0–1.75 mg. A further increase in the dose was only effective in 1
GH-/PRL-cosecreting adenoma.
The results of this study suggest that cabergoline is an effective,
well tolerated therapy that should be considered in the management
of acromegaly, especially if the pituitary adenoma cosecretes GH and
PRL or if pretreatment plasma IGF-I levels are below 750 mg/L.
(J Clin Endocrinol Metab 83: 374–378, 1998)
GH-SECRETING pituitary adenomas are the most com-mon cause of the acromegalic syndrome (1). About
one third of these adenomas are plurihormonal acidophil
cell-derived tumors and cosecrete PRL in addition to GH (2).
In view of the increased mortality associated with acromeg-
aly, successful management is of utmost importance, as re-
duction of the GH concentration below 2.5 mg/L produces a
shifting of the mortality rate into the normal range (3). Se-
lective resection of the adenoma by the transsphenoidal ap-
proach is the treatment of choice for acromegaly (4). How-
ever, when stringent standards of cure, such as serum GH
levels below 2 mg/L and normalization of plasma insulin-like
growth factor I (IGF-I) levels, are used, the global rate of
success of surgery is less than 50% (5). Effects of pituitary
radiation are usually not measured against these criteria and,
moreover, are slow to develop (6). These findings clearly
indicate the necessity for adequate adjunctive drug
treatment.
The most efficient drugs are currently the somatostatin
analogs, given either by multiple daily sc injections (7, 8) or
as a depot preparation once monthly (9, 10). A larger expe-
rience has been obtained with dopamine agonists, but com-
parative studies have shown that bromocriptine is less ef-
fective in the suppression of GH and IGF-I secretion than
octreotide (11, 12). Cabergoline is a new ergot derivative with
a prolonged duration of action and pronounced activity. In
the treatment of hyperprolactinemia it is superior to bro-
mocriptine in terms of efficacy and tolerability (13–15). As
cabergoline has not yet been tried in a large group of acro-
megalics, we, therefore, conducted an open labeled, multi-
center study in 64 acromegalic patients.
Subjects and Methods
Subjects
Sixty-four patients with active acromegaly, 27 men and 37 women,
aged 17–75 yr, were enrolled in this prospective, open labeled study.
Informed consent was obtained from all patients. Diagnosis of acro-
megaly was established by the demonstration of elevated serum GH
levels not suppressible below 2 mg/L after a 75-g oral glucose load and
elevated plasma IGF-I levels above 300 mg/L. As cosecretion of PRL has
been shown to be associated with a better clinical response to dopamine
agonist therapy (16), the patients were divided into 2 groups.
Group I consisted of 16 acromegalic patients, 9 men and 7 women,
aged 17–67 yr, with elevated serum PRL levels. Twelve patients had
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previously been treated. Surgery was performed in 7 and was followed
by radiotherapy in 1, bromocriptine in 2, and octreotide in 1 patient. As
primary treatment, bromocriptine was given to 3, and octreotide to 2
patients. Four patients had never received any treatment. A microad-
enoma was present in 4 subjects, and a macroadenoma in 9 cases,
whereas in 3 cases no tumor remnants could be found due to the
anatomical rearrangement after surgery. Cosecretion was established by
immunohistochemistry in 10 operated patients, as 3 more underwent
surgery after closure of the study. Cosecretion was assumed in the 6
other patients in the presence of a basal serum PRL level above 30 mg/L,
which, in addition, was not responsive to the administration of TRH.
Moreover, this assumption was supported in the 4 microadenomas by
the absence of a pituitary stalk compression that might have been re-
sponsible for hyperprolactinemia and in the remaining 2 macroadeno-
mas by a pronounced increase in the basal serum PRL levels, at 61 mg/L
in a 19-mm large tumor without stalk compression and at 879 mg/L in
a 30-mm large tumor, respectively.
Group II comprised 48 acromegalic patients, 18 men and 30 women,
aged 30–75 yr, with normal serum PRL levels. Primary treatment con-
sisted of surgery in 25 patients and radiotherapy in 2 others. Surgery was
followed by radiotherapy in 8, bromocriptine in 6, and octreotide in 12
patients. As primary treatment, bromocriptine was given to 1, and
octreotide to 2 patients. The remaining 18 patients had never received
any treatment. A microadenoma was present in 8 cases, and a mac-
roadenoma in 16 cases, whereas in 24 cases treated by surgery or ra-
diotherapy no tumor remnants were found.
Study design and drug administration
Cabergoline was proposed as an adjunctive treatment to patients not
cured by prior therapy and also as a primary treatment. Administration
of cabergoline was started at least 3 months after surgery or 3 yr after
radiotherapy, and 1 month after discontinuation of medical therapy. It
was initiated at a dose of one tablet of 0.5 mg twice weekly (1 mg/week)
given with the evening meal. The plasma IGF-I concentration was used
as parameter for adaptation of the dose because it reflects the integrated
GH secretion of the previous day. Hence, a normalization of the plasma
IGF-I level was considered to express a normalization of the GH pro-
duction (17). In case of insufficient therapeutic response, defined as a
plasma IGF-I level above 300 mg/L, the frequency of administration was
increased stepwise to a 0.5-mg dose every 2 days (1.75 mg/week), daily
(3.5 mg/week), and in one patient twice daily (7 mg/week). Plasma
IGF-I, serum GH, and PRL concentrations were measured randomly
before the start of the treatment, every 1–3 months during the dose-
establishing period, and every 4–6 months after normalization of the
IGF-I level. The treatment period varied between 3–40 months. In the
case of a lack of therapeutic efficacy, the study was discontinued after
3 months.
Evaluation of treatment efficacy
The criteria used to determine the efficacy of cabergoline were arbi-
trarily chosen. A good response was defined as a value less than 300
mg/L for IGF-I, less than 2 mg/L for GH, and less than 20 mg/L for PRL.
A moderate response was considered a value between 300–450 mg/L for
IGF-I, between 2–5 mg/L for GH, and between 20–50 mg/L for PRL. A
poor response was specified as a value more than 450 mg/L for IGF-I,
more than 5 mg/L for GH, and more than 50 mg/L for PRL. Furthermore,
pretreatment cut-off levels of 750 mg/L for plasma IGF-I and 20 mg/L
for serum GH were used as predictive values to assess the efficacy of
treatment.
Magnetic resonance imaging of the pituitary region was performed
at baseline, after 6 months of treatment, and then yearly. Reduction by
half of one of the diameters of the adenoma was defined as tumor
shrinkage by at least 50%.
Assays
Plasma IGF-I was measured by RIA (SM-C-RIA-CT, Medgenix Di-
agnostics, Fleurus, Belgium). Plasma concentrations are influenced by
age, but may be considered normal below 300 mg/L for the age group
of our patients. The interassay coefficient of variation was 10.2% at 38
mg/L, 6.7% at 169 mg/L, and 6.5% at 472 mg/L. Serum GH was measured
using a two-site immunoradiometric assay (Pharmacia Diagnostics hGH
RIA, Pharmacia, Uppsala, Sweden). The interassay coefficient of vari-
ation is 2.7% at 3.0 mg/L, 2.7% at 7.8 mg/L, and 2.1% at 15.8 mg/L. Serum
PRL was measured using a two-site immunoradiometric assay (RIA-
gnost Prolactin, Behringwerke, Marburg, Germany). Normal values are
less than 10 mg/L (350 mU/L) in males and less than 20 mg/L (700
mU/L) in females. The interassay coefficient of variation is 3.5% at 6.7
mg/L, 2.7% at 15.7 mg/L, and 3.2% at 39.6 mg/L.
Results
The treatment with cabergoline was well tolerated. Only
seven patients mentioned gastrointestinal discomfort or or-
thostatic hypotension at the start of treatment. Two patients,
both taking a dose of 1.75 mg/week, discontinued the treat-
ment because of nausea. No serious adverse events were
recorded.
For each patient individually, the plasma IGF-I concen-
tration at the end of treatment is depicted in relation to the
basal value in Fig. 1. A pretreatment plasma IGF-I level less
than 750 mg/L corresponds to a more consistent therapeutic
success. For all patients, evaluated as a single group, the
hormonal responses to the treatment are summarized in
Table 1.
Prior medical treatment with bromocriptine or octreotide
did not have a large impact on the therapeutic efficacy of
cabergoline when the plasma IGF-I level was used as crite-
rion. In the pretreated group, 36% of patients were consid-
ered good responders, 36% moderate responders, and 28%
poor responders, whereas in the nontreated group, the re-
sponse was good in 42% of patients, moderate in 22%, and
poor in 36%.
Group I
The global responses in GH-/PRL-cosecreting adenomas
are summarized in Table 1. The results for PRL were con-
sidered good in 14, moderate in 1, and poor in 1 patient. The
individual responses to the administration of increasing
doses of cabergoline are shown in Fig. 2.
Magnetic resonance follow-up studies were performed in
9 of 13 patients who initially presented radiological signs of
tumoral mass. A small regression in volume was observed in
1 microadenoma. A distinct shrinkage was found in 7 of 8
FIG. 1. Plasma IGF-I concentration for each patient individually at
the end of treatment in relation to the pretreatment concentration.
Open squares correspond to GH-/PRL-cosecreting adenomas in group
I; closed squares correspond to GH-secreting adenomas in group II.
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macroadenomas, and in 5, the mass reduction was at least
50%.
The weekly dose of cabergoline was 1.0 mg in eight pa-
tients and 1.75 mg in seven patients. Only in a 17-yr-old man
with gigantism and hyperprolactinemia since the age of 9 yr
was the dose progressively increased to 3.5 and 7 mg/week.
This resulted in a further amelioration of the hormonal pa-
rameters and necrosis of the adenoma.
Group II
The global responses in pure GH-secreting adenomas are
summarized in Table 1. The individual responses to the
administration of an increasing dose of cabergoline are
shown in Fig. 3.
Magnetic resonance follow-up studies were performed in
12 of 24 patients showing radiological signs of tumoral mass.
FIG. 2. The upper squares indicate the pretreatment plasma IGF-I,
serum GH, and PRL concentrations in the GH-/PRL-cosecreting ad-
enomas in group I. The lower squares correspond to the concentrations
obtained by progressively increasing the weekly dose of cabergoline,
i.e. 1.0, 1.75, 3.5, and 7.0 mg, respectively. Note the log scale for GH
and PRL.
FIG. 3. The upper squares indicate the pretreatment plasma IGF-I
and serum GH concentrations in the GH-secreting adenomas in group
II. The lower squares correspond to the concentrations obtained by
progressively increasing the weekly dose of cabergoline, i.e. 1.0, 1.75,
and 3.5 mg, respectively. Note the log scale for GH.
TABLE 1. Therapeutic response according to pretreatment IGF-I and GH concentrations














All (n 5 64) 25 (39) 18 (28) 21 (33) 30 (46) 17 (27) 17 (27)
IGF-I ,750 mg/L (n 5 40) 21 (53) 13 (32) 6 (15) 24 (60) 12 (30) 4 (10)
IGF-I .750 mg/L (n 5 24) 4 (17) 5 (21) 15 (62) 6 (25) 5 (21) 13 (54)
GH ,20 mg/L (n 5 48) 23 (48) 15 (31) 10 (21) 29 (61) 15 (31) 4 (8)
GH .20 mg/L (n 5 16) 2 (12) 3 (19) 11 (69) 1 (6) 2 (13) 13 (81)
Group I (GH/PRL-secreting)
All (n 5 16) 8 (50) 5 (31) 3 (19) 9 (56) 4 (25) 3 (19)
IGF-I ,750 mg/L (n 5 10) 8 (80) 2 (20) 0 (0) 8 (80) 2 (20) 0 (0)
IGF-I .750 mg/L (n 5 6) 0 (0) 3 (50) 3 (50) 1 (17) 2 (33) 3 (50)
GH ,20 mg/L (n 5 13) 8 (62) 5 (38) 0 (0) 9 (69) 4 (31) 0 (0)
GH .20 mg/L (n 5 3) 0 (0) 0 (0) 3 (100) 0 (0) 0 (0) 3 (100)
Group II (GH-secreting)
All (n 5 48) 17 (35) 13 (27) 18 (38) 21 (44) 13 (27) 14 (29)
IGF-I ,750 mg/L (n 5 30) 13 (43) 11 (37) 6 (20) 16 (54) 10 (33) 4 (13)
IGF-I .750 mg/L (n 5 18) 4 (22) 2 (11) 12 (67) 5 (28) 3 (17) 10 (55)
GH ,20 mg/L (n 5 35) 15 (42) 10 (29) 10 (29) 20 (58) 11 (31) 4 (11)
GH .20 mg/L (n 5 13) 2 (15) 3 (23) 8 (62) 1 (8) 2 (15) 10 (77)
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No reduction in volume was observed in 3 microadenomas.
A distinct shrinkage was found in 5 of 9 macroadenomas, but
none reached a 50% mass reduction.
The weekly dose of cabergoline was 1.0 mg in 13 patients
and 1.75 mg in 28 patients. A further increase in the dose to
3.5 mg/week in 7 poorly responding patients could not sup-
press the IGF-I secretion more efficaciously.
Discussion
Dopamine agonists have been widely used in the treat-
ment of acromegaly since the availability of bromocriptine in
1974, and more than 30 clinical studies have been published
evaluating the effect of this medication (18). However, am-
biguous criteria used to define therapeutical efficacy, mostly
a more than 50% reduction of the GH concentration, make
interpretation of the available data difficult. In general, sup-
pression of GH secretion to a serum concentration of less than
5 mg/L and normalization of the plasma IGF-I level, which
are more stringent criteria of adequate therapy, are only
obtained in 20% and 10% of acromegalic patients, respec-
tively. Compared to prolactinomas, the treatment of acro-
megaly usually requires a more frequent daily intake and a
higher dose of bromocriptine. Some of the constraints could
be avoided by using the long acting and repeatable im form
of bromocriptine or apomorphine derivatives such as
quinagolide. However, the few reports concerning the effi-
cacy of these two drugs in the treatment of acromegaly also
emphasize that normalization of plasma IGF-I levels is only
obtained in a limited number of patients (19, 20).
This is the first multicenter trial with cabergoline, a long
acting, orally administered dopamine agonist, in a large se-
ries of unselected acromegalic patients. We showed that a
decrease in IGF-I below 300 mg/L can be obtained in 39% of
patients, and a decrease in GH below 2 mg/L can be obtained
in 46% of patients. In addition, a suppression of IGF-I be-
tween 300–450 mg/L is obtained in another 28% of patients,
and a suppression of GH between 2–5 mg/L is obtained in
another 27% of patients. These results are much better than
the data previously reported for bromocriptine. This can be
explained to some extent by a superior pharmacological pro-
file of cabergoline. Compared to bromocriptine, cabergoline
has a more specific D2 receptor-binding capacity and pos-
sesses a much longer half-life than bromocriptine. This
avoids large fluctuations in dopamine agonist activity and
both enhances clinical efficacy and reduces side-effects, as
has been shown in a double blind study of patients with
hyperprolactinemia (14). This pharmacological advantage
may be of even greater importance in acromegaly than in
hyperprolactinemia, as much higher doses of dopamine ag-
onist activity are required.
Similar to bromocriptine therapy (16), two factors were
predictive for the ultimate therapeutic response to cabergo-
line in our study. First, the activity of acromegaly, as reflected
by IGF-I or GH levels, is a negative factor, as normalization
was less frequently obtained in patients with initial values
above 750 or 20 mg/L, respectively. Second, a more pro-
nounced inhibitory response was found in patients cosecret-
ing PRL. Although immunohistochemical evidence of cose-
cretion could not be demonstrated in each patient, the
therapeutic response, assessed by determination of hormone
levels and radiological examination, was clearly superior in
group I.
The high number of acromegalic patients with normalized
IGF-I levels during cabergoline treatment in our study must
probably also be explained by a bias in patient selection.
Indeed, some of our patients had been treated by surgery
and/or radiotherapy and had only moderate elevations of
IGF-I. Also, some patients included in the present study had
initial GH levels below 5 mg/L and would have been con-
sidered cured in earlier studies. However, even when pa-
tients with high IGF-I levels (.750 mg/L) were considered,
17% of normalized IGF-I values meant a doubling of success
compared to the effect of bromocriptine therapy.
Until now, the therapeutic effect of cabergoline in ac-
romegaly has been reported in 3 smaller studies. In the
first, normal plasma IGF-I levels were obtained in 3 of 6
patients with a weekly dose of 0.3– 0.6 mg (21). An increase
in the dose to 1.2 mg in the 3 other patients was insufficient
to reach normalization of IGF-I. In the second study, 11
patients were treated with a weekly dose of cabergoline
between 1.0 –2.0 mg (22); this resulted in a significant
decrease in plasma IGF-I levels, but without normalization
in any of the patients. In the last study, 10 patients each
received a dose of 3.5 mg cabergoline/week (23). Substan-
tial decreases in plasma IGF-I and GH were observed in 7
patients, and biochemical remission was achieved in 2 of
them. An increase in the dose to 7.0 mg did not improve
the efficacy, but induced intolerability.
Therapy with cabergoline was well tolerated, even at the
higher doses. Only two patients (3%) stopped treatment be-
cause of side-effects. This confirms data from comparative
studies using bromocriptine, in which 12% of patients dis-
continued therapy, whereas this was the case in only 3% of
patients treated with cabergoline (14). In analogy to other
dopamine agonists, rare cases of pleuropulmonary disease
have been reported with large doses of cabergoline (up to 10
mg daily) for Parkinson’s disease (24), but this seems un-
likely to occur with the dose employed in our study.
In conclusion, cabergoline represents a valuable new tool
in the therapeutic arsenal for acromegaly. Although not for-
mally proven by a double blind study, its superiority to
bromocriptine seems clear, as is the case in the treatment of
prolactinomas. Cabergoline will, therefore, reinforce the role
of dopamine agonists in the treatment of acromegaly, par-
ticularly in patients with moderately elevated plasma IGF-I
levels and/or in the case of cosecretion of PRL.
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